Qizheng Tibetan Medicine announced its first-half performance report on August 17. From January to June 2017, it realized operating income of RMB 528,828,500, an increase of 4.19% over the same period of the previous year, and realized operating profit of RMB 189,979,700, an increase of 5.16% over the same period of the previous year. The net profit attributable to shareholders of listed companies was 169,649,100 yuan, an increase of 5.20% over the same period of the previous year.
Qizheng Tibetan Medicine said that 2017 is the year of the company's three-year strategy, and the company continues to carry out its business around the strategy of “one axis, two wings and one supportâ€. Facing the ever-changing policies and market challenges, the company further focused on medical value mining, flexibly adjusted marketing strategies, rationally allocated market resources, strengthened team execution, actively promoted new product development, and maintained steady growth in performance.
The large hospital market, on the one hand, adheres to the brand-driven academic marketing strategy, increases academic marketing investment, and promotes the clinical value of products in the treatment of related diseases through high-level evidence-based medical evidence, providing customers with better clinical solutions; Increase the listing of new products and achieve rapid coverage.
The basic drug market continues to expand the terminal coverage of all products, relying on the brand advantage established by the pain-relieving paste in large hospitals, and the diversion of patients after grading diagnosis and treatment, to achieve product accessibility and availability, and to promote further sales growth.
The retail market, around the pain integrated brand development strategy, relying on the continuous improvement of personnel capabilities, through systematic management of key customers, strengthen deep cooperation, enrich the form of activities, enhance channel distribution coverage, on the one hand, consolidate the market leading position of pain relief paste On the one hand, we will expand the pain-integrated product group and rapidly increase the coverage of second-line products.
In terms of manufacturing, in the first half of the year, the company continued to improve its manufacturing capabilities in strict accordance with GMP management regulations. Subsidiary Gannan Foge Tibetan Medicine Co., Ltd. obtained the GMP certificate for tablet line; Tibet Linzhi Yutuo Tibetan Medicine Co., Ltd. passed the GMP certification inspection; at the same time, continuously strengthen the daily management of production, quality and safety, and strengthen the training of all relevant personnel. And continue to improve production efficiency through technical improvement, employee operation skills, to meet multi-product and multi-standard sales needs.
The main business of Qizheng Tibetan Medicine is the research and development, production and sales of Tibetan medicine. The main drugs include external series products such as Xiaotong plaster, Qingpeng ointment and Baimai ointment, and oral Tibetan medicine products such as Honghua Ruyi Pill. . The income of various products in the first half of 2017 is as follows:
Wireless Smoke Detector,Wifi Smoke Detector,Photoelectric Smoke Alarm,Wireless Smoke Alarms
NINGBO TOMAN IMP. & EXP. CO., LTD , https://www.tdotmfiresolution.com